{"schema_version":"secwatch.filing_event.v1","accession":"0001932393-24-000033","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.240978+00:00","generated_at":"2026-06-03T04:50:37.157622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GE HealthCare reports Q1 2024 results: revenue flat organically, margins expand, reaffirms guidance","bullets":["Revenues declined 1% to $4.6B; organic revenue approximately flat year-over-year.","Net income margin improved to 8.0% from 7.9%; Adjusted EBIT margin rose to 14.7% from 14.1%.","Diluted EPS increased to $0.81 from $0.41; Adjusted EPS rose to $0.90 from $0.85.","Cash from operations $419M vs $468M; free cash flow $274M vs $325M; repaid $150M debt.","Reaffirmed full-year 2024 guidance: ~4% organic revenue growth, Adjusted EPS $4.20-$4.35."],"urls":{"canonical":"https://secwatch.observer/filing/0001932393-24-000033","json":"https://secwatch.observer/filing/0001932393-24-000033.json","markdown":"https://secwatch.observer/filing/0001932393-24-000033.md","text":"https://secwatch.observer/filing/0001932393-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000193239324000033/0001932393-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000193239324000033/gehc-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:50:37.157622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f41b5ac98f407b0bec61db3275a0982c21038e","claim":"GE HealthCare Technologies Inc. reported the first quarter ended March 31, 2024 results: revenue $4.6 billion, net income $374 million, EPS $0.81. Guidance reaffirmed.","evidence_excerpt":"of 2024 consistent with our previous comments, and we remain on track to deliver our guidance for the year.” First Quarter 2024 Total Company Financial Performance • Revenues of $4.6 billion declined 1% r eported and were approximately flat on an Organic* basis year-over-year, with decreased volume partially offset by positive price. • Total company book-to-bill was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239324000033/0001932393-24-000033-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$4.6 billion"},{"label":"Net income","value":"$374 million"},{"label":"EPS","value":"$0.81"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}